All In Biotech

Drug Trial Radar · NCT05581199

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

94

Actual

Start

Dec 15, 2022

Primary completion

Jul 20, 2026

Study completion Jul 20, 2026

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin \[Ig\] or plasma exchange \[PLEX\]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • Batoclimab 680 milligrams (mg) subcutaneous (SC) weeklyDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • Batoclimab 340 mg SC weeklyDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • PlaceboDrug

    Matching placebo SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 2, Cohort A: Proportion of participants who remain relapse-free at Week 36Time frame: Week 36

Locations

98 sites in 21 countries. Site status is shown where the registry gives one.

  • Site Number - 1603

    Scottsdale, Arizona

  • Site Number - 1634

    Los Angeles, California

  • Site Number - 1625

    Aurora, Colorado

  • Site Number - 1621

    New Haven, Connecticut

  • Site Number - 1629

    Orlando, Florida

  • Site Number - 1617

    Ormond Beach, Florida

  • Site Number - 1620

    Port Charlotte, Florida

  • Site Number - 1633

    Rockledge, Florida

  • Site Number - 1604

    St. Petersburg, Florida

  • Site Number - 1602

    Kansas City, Kansas

  • Site Number - 1611

    Nicholasville, Kentucky

  • Site Number - 1605

    New York, New York

  • Site Number - 1610

    Charlotte, North Carolina

  • Site Number - 1614

    Portland, Oregon

  • Site Number - 1623

    Philadelphia, Pennsylvania

  • Site Number - 1624

    Philadelphia, Pennsylvania

  • Site Number -1601

    Austin, Texas

  • Site Number - 1606

    Houston, Texas

  • Site Number - 1628

    San Antonio, Texas

  • Site Number - 1632

    Seattle, Washington

  • Site Number - 1613

    Milwaukee, Wisconsin

  • Site Number - 7750

    Buenos Aires, Argentina

  • Site Number - 7753

    Rosario, Santa Fe Province, Argentina

  • Site Number - 7751

    Rosario, Santa Fe Province, Argentina

  • Site Number - 7752

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Site Number - 4681

    Ghent, Oost-Vlaanderen, Belgium

  • Site Number - 4680

    Leuven, Vlaams Brabant, Belgium

  • Site Number - 9105

    São Paulo, Brazil

  • Site Number - 9103

    Brasília, Federal District, Brazil

  • Site Number - 9101

    Curitiba, Paraná, Brazil

  • Site Number - 9100

    Ribeirão Preto, São Paulo, Brazil

  • Site Number - 9112

    Pleven, Bulgaria

  • Site Number - 9111

    Sofia, Sofia-Grad, Bulgaria

  • Site Number - 9110

    Sofia, Sofia-Grad, Bulgaria

  • Site Number - 2600

    Edmonton, Alberta, Canada

  • Site Number - 2603

    Vancouver, British Columbia, Canada

  • Site Number - 4740

    Copenhagen, Denmark

  • Site Number - 3241

    Turku, Southwest Finland, Finland

  • Site Number - 6706

    Berlin, Germany

  • Site Number - 6705

    Bochum, North Rhine-Westphalia, Germany

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.